Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.68 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.66 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8293519 | 0.90 | CYP4A11 (0.62) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL16523044 | 0.86 | CYP4A11 (0.62) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL9206449 | 0.85 | CYP4A11 (0.66) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL70185 | 0.82 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL16542460 | 0.81 | CYP4A11 (0.60) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL29055656 | 0.81 | CYP4A11 (0.60) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL24370665 | 0.81 | GRIN2D (0.71) | GRIN2DGRIN2AGRIN2BGRIN2CALDH1A1 | |
| SCHEMBL10609552 | 0.81 | CYP4A11 (0.74) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL31276855 | 0.81 | HSD17B10 (0.61) | CYP4A11CYP4F2GRIN2DGRIN2AGRIN2B | |
| SCHEMBL2654777 | 0.81 | CYP4A11 (1.00) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
| EP-3510022-B1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-05 | — | — | EP | disclosed |
| CN-110072858-A | Indole derivatives as glucagon receptor antagonist | 詹森药业有限公司 | 2019-07-30 | — | — | CN | disclosed |
| EP-3510022-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | Janssen Pharmaceutica NV (BE) | 2019-07-17 | — | — | EP | disclosed |
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-09 | — | — | US | disclosed |
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-09 | — | — | US | disclosed |
| WO-2018048761-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | WO | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| WO-2012054364-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251864-B2 | Indole derivatives useful as glucagon receptor antagonists | GPR119, GIPR, GLP1R | CYP4A11 921/4885CYP4F2 2231/4885LOXL2 1651/4885 |
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | CYP4A11 44/4885CYP4F2 58/4885LOXL2 4609/4885 |
| US-20180064686-A1 | INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GIPR, GLP1R | CYP4A11 921/4885CYP4F2 2231/4885LOXL2 1651/4885 |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | CYP4A11 2671/4885CYP4F2 2973/4885LOXL2 3103/4885 |
| US-20110294775-A1 | NOVEL COMPOUNDS | TRPV1, OPRL1, TRPA1 | CYP4A11 3601/4885CYP4F2 3655/4885LOXL2 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.